超膜大动脉狭窄症在同胞性家族高胆固醇血症:当代管理当代管理
Scott Eisenberg1, Daniel Gold2, Puja K Mehta2
1Emory University School of Medicine, Atlanta, Georgia, USA.
JACC. Case reports
|April 29, 2024
概括
本案例研究详细介绍了与渐进的上膜大动脉狭窄症相结合的同卵性家族性高胆固醇血症的管理. 有效的治疗涉及低密度脂蛋白缩和新型降脂剂,显著降低LDL胆固醇水平.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 家族性高胆固醇血症 (FH) 是一种遗传性疾病,导致胆固醇水平升高.
- 同胞性FH (HoFH) 呈现出严重的高胆固醇血症和早发性心血管疾病.
- 上大动脉狭窄是一种罕见的先天性心脏缺陷,可能与某些遗传条件有关.
研究的目的:
- 介绍一个患有同胞性家族性高胆固醇血症和渐进的上膜大动脉狭窄症的病例.
- 描述这种复杂的患者形象所采用的管理策略.
- 突出这些病例的治疗挑战和结果.
主要方法:
- 长期的低密度脂蛋白 (LDL) 脱脂被用于降低LDL胆固醇.
- 新的降脂剂,包括一种血管类蛋白质 (ANGPTL) 抑制剂,被使用.
- 临床监测脂质配置文件和心血管状况进行.
主要成果:
- 通过综合治疗方法实现了低密度脂蛋白胆固醇水平的显著降低.
- 管理策略在控制高胆固醇血症方面表现出有效性.
- 患者的病例为先进疗法的实际应用提供了洞察力.
结论:
- 管理同卵性家族性高胆固醇血症与同时存在的上膜大动脉狭窄症具有重大临床挑战.
- 结合LDL疏散和新型药理学药物,可以有效降低LDL胆固醇.
- 这一案例强调了针对罕见和严重的脂质疾病的量身定制,积极的治疗策略的重要性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
652
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
652
Cystic Fibrosis: Management
157
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
157
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
148
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
148
Esophageal Varices-II: Clinical Features and Management
60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60


